Barclays
SPRB

Barclays’s Spruce Biosciences SPRB Stock Holding History

Barclays’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100
Closed -$16.5K – 5171
2023
Q1 		$16.5K Sell
100
-2
-2% -$371 ﹤0.01% 4686
2022
Q4 		$8.38K Sell
102
-51
-33% -$4.27K ﹤0.01% 4944
2022
Q3 		$15K Hold
153
– – ﹤0.01% 4171
2022
Q2 		$20K Sell
153
-16
-9% -$2.05K ﹤0.01% 4415
2022
Q1 		$25K Buy
+169
New +$31.4K ﹤0.01% 4381

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Barclays's SPRB Position: Q2 2023 in Review

Barclays sold out of Spruce Biosciences (SPRB) in Q2 2023, closing a stake of 100 shares — an estimated $16.5K sold.

Barclays first reported a position in SPRB in Q1 2022 and held it in 5 quarters. The position peaked at $25K in Q1 2022. 38 funds tracked by Wall St. Rank hold SPRB as of Q2 2023.

  • Barclays reported no remaining Spruce Biosciences position as of Q2 2023 after selling out during the quarter.
  • Barclays sold 100 Spruce Biosciences shares in Q2 2023, an estimated $16.5K.
  • Barclays first reported a position in Spruce Biosciences in Q1 2022 and held it in 5 quarters.
  • Barclays's Spruce Biosciences position peaked at $25K in Q1 2022.
  • 38 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.